MGRXHIGH SIGNALFINANCIAL10-K

MGRX experienced a severe deterioration in operating performance with net losses more than doubling to $20.6M despite a dramatic improvement in cash position to $1.5M.

The company's core business fundamentals are rapidly deteriorating, with revenue declining 26% while operating losses expanded 126% to $18M, indicating severe operational inefficiencies or unsustainable business model issues. While the massive cash increase suggests recent financing activity, this appears to be a lifeline for a company burning through capital at an accelerating rate.

Comparing 2026-04-01 vs 2025-03-20View on EDGAR →
FINANCIAL ANALYSIS

MGRX shows a tale of two extremes - cash and equivalents surged an extraordinary 2,434% to $1.5M while current liabilities decreased 37.5%, suggesting recent equity financing or debt restructuring. However, core operations deteriorated severely with revenue falling 26% to $456K, gross profit declining 34%, and most critically, net losses more than doubling to $20.6M from $8.7M. The combination of declining revenue growth with exponentially increasing losses signals fundamental business model problems that the recent cash infusion may only temporarily address.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+2434.1%
$59K$1.5M

Cash position surged 2434.1% — strong cash generation or capital raise providing significant financial cushion.

Current Assets
Balance Sheet
+1947%
$76K$1.5M

Current assets grew 1947% — improving short-term liquidity or inventory/receivables build.

Interest Expense
P&L
-200%
$6K-$6K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Net Income
P&L
-137.1%
-$8.7M-$20.6M

Net income declined 137.1% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-126.2%
-$8.0M-$18.0M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Capital Expenditure
Cash Flow
-91.8%
$43K$4K

Capex reduced 91.8% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Total Liabilities
Balance Sheet
-37.5%
$1.4M$891K

Liabilities reduced 37.5% — deleveraging improves balance sheet strength and financial flexibility.

Current Liabilities
Balance Sheet
-37.5%
$1.4M$891K

Current liabilities reduced — improved short-term financial position and working capital health.

Gross Profit
P&L
-34.1%
$380K$250K

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Revenue
P&L
-26%
$616K$456K

Revenue softened 26% — monitor whether this is cyclical or structural.

LANGUAGE CHANGES
NEW — 2026-04-01
PRIOR — 2025-03-20
ADDED
As of March 31, 2026, the registrant had 16,967,420 shares of its Common Stock, $ 0.0001 par value, outstanding.
These statements are not guarantees of future performance or results.
Reverse Stock Split On October 8, 2024, we filed a Certificate of Amendment to our Certificate of Formation, as amended and restated (the Certificate of Amendment ) with the Secretary of State of the State of Texas to affect a reverse stock split of our common stock at a ratio of 1-for-15 (the Reverse Stock Split ).
The shares of the Company s common stock began trading on the Nasdaq Capital Market ( Nasdaq ) on a post-split basis on October 16, 2024.
Organizational History We are a Texas corporation formed on October 7, 2021.
+7 more — sign up free →
REMOVED
As of March 20, 2025, the registrant had 5,168,796 shares of its Common Stock, $ 0.0001 par value, outstanding.
On October 7, 2024, the Company s Board of Directors (the Board ), with the Stockholder Authority, approved an amendment to our Certificate of Formation, as amended and restated, to effect a reverse stock split of our common stock at a ratio of 1-for-15 (the Reverse Stock Split ).
On October 8, 2024, we filed a Certificate of Amendment to our Certificate of Formation, as amended and restated (the Certificate of Amendment ) with the Secretary of State of the State of Texas to affect the Reverse Stock Split.
The shares of the Company s common stock began trading on the Nasdaq Capital Market ( Nasdaq ) on a post-split basis on October 16, 2024, with new CUSIP number: 56270V205.
Food and Drug Administration ( FDA ) approved form of oral testosterone undecanoate to treat low testosterone in men and as a form of Testosterone Replacement Therapy (TRT), developed and produced by Marius Pharmaceuticals, Inc.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →